Women at all stages of disease have greater tau burden than men as measured at autopsy, via tau-PET and cerebrospinal fluid (CSF) measures,13, 14 and this difference in tau burden is even more apparent if they carry APOE-ε43, 13, 28 or have abnormal amyloid burden.13 Studies also demonstrate that women experience faster cognitive decline in response to tau pathology, especially if they are Aβ-positive and carry APOE-ε4.3, 29 Taken together, these findings provide evidence for transcriptomic pathways that underlie the well-characterized clinical findings of sex differences in AD risk. Here, MAPT is linked to Alzheimer disease.